Adipose tissue engineering based on the controlled release of fibroblast growth factor-2 in a collagen matrix.
Adipose tissue forms when basement membrane extract (Matrigel) and fibroblast growth factor-2 (FGF-2) are added to our mouse tissue engineering chamber model. A mouse tumor extract, Matrigel is unsuitable for human clinical application, and finding an alternative to Matrigel is essential. In this study we generated adipose tissue in the chamber model without using Matrigel by controlled release of FGF-2 in a type I collagen matrix. FGF-2 was impregnated into biodegradable gelatin microspheres for its slow release. The chambers were filled with these microspheres suspended in 60 microL collagen gel. Injection of collagen containing free FGF-2 or collagen containing gelatin microspheres with buffer alone served as controls. When chambers were harvested 6 weeks after implantation, the volume and weight of the tissue obtained were higher in the group that received collagen and FGF-2 impregnated microspheres than in controls. Histologic analysis of tissue constructs showed the formation of de novo adipose tissue accompanied by angiogenesis. In contrast, control groups did not show extensive adipose tissue formation. In conclusion, this study has shown that de novo formation of adipose tissue can be achieved through controlled release of FGF-2 in collagen type I in the absence of Matrigel.
Vashi
Aditya V
AV
Bernard O'Brien Institute of Microsurgery, St. Vincent's Hospital, Fitzroy, Victoria, Australia. aditya.vashi@svhm.org.au
Abberton
Keren M
KM
Thomas
Gregory P
GP
Morrison
Wayne A
WA
O'Connor
Andrea J
AJ
Cooper-White
Justin J
JJ
Thompson
Erik W
EW
D000273:Adipose Tissue / Q000098:blood supply / Q000166:cytology / Q000187:drug effects / Q000502:physiology* / Q000637:transplantation; D000818:Animals; D001672:Biocompatible Materials / Q000378:metabolism; D002021:Buffers; D024042:Collagen Type I / Q000378:metabolism*; D003692:Delayed-Action Preparations; D005109:Extracellular Matrix / Q000378:metabolism*; D016222:Fibroblast Growth Factor 2 / Q000378:metabolism* / Q000494:pharmacology; D005780:Gelatin / Q000378:metabolism; D006801:Humans; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008863:Microspheres; D013997:Time Factors; D023822:Tissue Engineering / Q000379:methods*
D001672:Biocompatible Materials; D002021:Buffers; D024042:Collagen Type I; D003692:Delayed-Action Preparations; D016222:Fibroblast Growth Factor 2; D005780:Gelatin